SCHEMBL4502928

SCHEMBL4502928

CCc1nc2cc(F)ccc2c(=O)n1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ ATM Q13315 1/20 0.47
▸ TSHR P16473 1/20 0.46
▸ RAB9A P51151 3/20 0.43
▸ USP2 O75604 1/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TRPV4 Q9HBA0 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ HTR3A P46098 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MPO P05164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28678736 0.85 ATM (0.68) LMNASMN1; SMN2ATMTSHRRAB9A
SCHEMBL27899324 0.80 KDM4E (0.61) LMNASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3714715 0.78 SMN1; SMN2 (0.71) LMNASMN1; SMN2ATMTSHRRAB9A
SCHEMBL1302241 0.77 KDM4E (0.39) GLAKMT2ATRPV4KDM4EL3MBTL1
SCHEMBL1161773 0.73 HDAC6 (0.42) ATMTSHRUSP2HDAC1HDAC2
SCHEMBL3700456 0.72 ATM (0.57) SMN1; SMN2ATMTRPV4MPO
SCHEMBL1302732 0.72 TRPV4 (0.49) LMNASMN1; SMN2TSHRRAB9ANPC1
SCHEMBL3066018 0.72 HDAC1 (0.47) LMNARAB9AUSP2NPC1HDAC1
SCHEMBL1161767 0.71 L3MBTL1 (0.44) TSHRRAB9ANPC1HDAC8HDAC6
SCHEMBL12605331 0.71 ESR1 (0.60) LMNASMN1; SMN2HDAC1HDAC2HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291973-A1 Novel Quinazoline Derivatives and Their Medical Use NEUROSEARCH A/S (DK) 2009-11-26 — — US disclosed
EP-1951685-A1 NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2008-08-06 — — EP disclosed
WO-2007057447-A1 NOVEL QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291973-A1 Novel Quinazoline Derivatives and Their Medical Use KCNA7, KCNN3, KCNQ5 LMNA 3396/4885SMN1; SMN2 1908/4885ATM 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback